Article Text

PDF
SAT0234 Prospective single centre study of effectiveness of upfront rituximab and mycophenolate with minimum steroid in sle
  1. BG Dharmanand
  1. Rheumatology, Sakra World Hospital, Sy No.52/2 & 52/3, Devarabeesanahalli, Oppsite Intel, Varthur Hobli, Bengaluru, Karnataka 560103, Bangalore, India

Abstract

Background Treatment options for SLE have significant morbidity and mortality. Side effects from corticosteroid usage limit patient adherence and treatment efficacy. B cell depletion appears to target a critical pathophysiological pathway in SLE. Trails with rituximab have shown mixed results. Rituxilup study demonstrated efficacy and steroid sparing action of rituximab and mycophenolate (1)

Objectives We aim to analyse our experience of using rituximab and mycophenolate upfront on presentation with minimum oral steroids.

Methods 12 patients with SLE, seen between Jan 2015 to march 2016, were included in the study. All patients completed 6 months of follow-up. Patients were treated with 2 doses of rituximab (1 g) and methyl prednisolone (500 mg) on days 1 and 15, and maintenance treatment of mycophenolate mofetil (2000mg) and low dose prednisolone (<7.5 mg) which was tapered off.

Results 10 were females and 2 males. Mean age of the patients is 24.5. 9 had lupus nephritis, 1 mesenteric vasculitis, 1 CNS vasculitis and 1 severe cutaneous vasculitis with pancytopenia. Average SLEDAI improved from 14 to 4. 6/9 LN attained complete renal remission and 2 partial remission. one patient died due to infection and renal disease 15 days after infusion. 2 vasculitis and one NPSLE patient improved completely. Two patients had infection requiring hospitalization with in 8 weeks of infusion and one patient had severe bradycardia during the infusion and received only 1000mg rituximab. Steroid was stopped by 6 months in 6 patients and in the dose was below 5 mg in rest.

Conclusions Early Rituximab and mycophenolate is an effective option for treating severe lupus and has steroid sparing property.

References

  1. Condon MB, Ashby D, Pepper RJ, et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis (2013) 72:1280–1286.

References

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.